Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for heart failure
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heart failure or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on heart failure and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Efficacy of telemedical interventional management in patients with heartfailure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial. Remote patient management in patients with heartfailure might help to detect early signs and symptoms of cardiac decompensation, thus enabling a prompt initiation of the appropriate treatment and care before a full manifestation of a heartfailure decompensation. We aimed to investigate the efficacy of our remote patient management intervention (...) on mortality and morbidity in a well defined heartfailure population.The Telemedical Interventional Management in HeartFailure II (TIM-HF2) trial was a prospective, randomised, controlled, parallel-group, unmasked (with randomisation concealment), multicentre trial with pragmatic elements introduced for data collection. The trial was done in Germany, and patients were recruited from hospitals and cardiology practices. Eligible patients had heartfailure, were in New York Heart Association class II or III
2018LancetControlled trial quality: predicted high
Iron deficiency in chronic heartfailure: caseâ€based practical guidance In patients with chronic heartfailure, iron deficiency, even in the absence of anaemia, can aggravate the underlying disease and have a negative impact on clinical outcomes and quality of life. The 2016 European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic heartfailure recognize iron deficiency as a co-morbidity in chronic heartfailure and recommend iron status screening in all (...) newly diagnosed patients with chronic heartfailure. Furthermore, the guidelines specifically recommend considerations of intravenous iron therapy, ferric carboxymaltose, for the treatment of iron deficiency. However, in spite of these recommendations, iron deficiency remains often overlooked and undertreated. This may be due, in part, to the lack of clinical context and practical guidance accompanying the guidelines for the treating physician. Here, we provide practical guidance complemented
, fluid retention, and fatigue; and signs including basal crepitations, and peripheral oedema. Heartfailure is (...) classified into two main categories with either a reduced or preserved ejection fraction. Symptoms are classified according to severity using the New York Heart Association (NYHA) functional classification. The most common underlying cause is coronary artery disease. Complications include arrhythmias, depression, cachexia, chronic kidney disease, sexual dysfunction, and sudden cardiac (...) Factors for HF ( Hypertension , Diabetes Mellitus, Metabolic Syndrome, and Atherosclerotic Disease) e249 5. Cardiac Structural Abnormalities 2013 8. Evaluation and Management of Right-Sided HeartFailure : A Scientific Statement From the American Heart Association Evaluation and Management of Right-Sided HeartFailure : A Scientific Statement From the American Heart Association | Circulation Search for this keyword Search Search for this keyword Search Header Publisher Menu AHA Scientific Statement
Sex differences in outcomes of heartfailure in an ambulatory, population-based cohort from 2009 to 2013 Heartfailure remains a substantial cause of morbidity and mortality in women. We examined the sex differences in heartfailure incidence, mortality and hospital admission in a population-based cohort.All Ontario residents who were diagnosed with heartfailure in an ambulatory setting between Apr. 1, 2009, and Mar. 31, 2014, were included in this study. Incident cases of heartfailure were (...) captured through physician billing using a validated algorithm. Outcomes were mortality and hospital admission for heartfailure within 1 year of the diagnosis. Probability of death and hospital admission were calculated using the Kaplan-Meier method. The hazard of death was assessed using a multivariable Cox proportional hazard model.A total of 90 707 diagnoses of heartfailure were made in an ambulatory setting during the study period (47% women). Women were more likely to be older and more frail
Haemodynamic effects of percutaneous mitral valve edgeâ€toâ€edge repair in patients with endâ€stage heartfailure awaiting heart transplantation Functional mitral regurgitation is complicating end-stage heartfailure and potential heart transplantation by increasing pulmonary artery pressures. The aim of the present study was to investigate feasibility and haemodynamic effects of percutaneous mitral valve edge-to-edge repair using the MitraClip™ device in patients with end-stage heart (...) failure awaiting heart transplantation.In this retrospective study, we identified nine patients suffering from end-stage heartfailure listed for heart transplantation in whom moderate-severe or severe functional mitral regurgitation was recognized and treated with percutaneous mitral valve edge-to-edge repair. Twenty-two patients listed for heart transplantation and presenting with moderate-severe or severe functional mitral regurgitation treated in the pre-MitraClip™ era served as controls. Patients
The effects of a low-carbohydrate diet on oxygen saturation in heartfailure patients: a randomized controlled clinical trial. Nutritional therapy in heartfailure (HF) patients has been focused on fluid and sodium restriction with the aim of decreasing volume overload. However, these recommendations are not well established and sometimes controversial.To evaluate the effect of the consumption of a low-carbohydrate diet on oxygen saturation, body composition and clinical variables during two (...) months of follow-up in chronic, stable heartfailure patients.In a parallel group randomized controlled clinical trial, 88 ambulatory patients were randomly assigned to a low-carbohydrate diet group (40% carbohydrates, 20% protein and 40% fats [12% saturated, 18% monounsaturated and 10% polyunsaturated]) or a standard diet group (50% carbohydrates, 20% protein and 30% fats [10% saturated, 10% monounsaturated and 10% polyunsaturated]) for two months. Diets were normocaloric in both groups. At baseline
Effect of the self-management education program on the quality of life in people with chronic heartfailure: a randomized controlled trial Chronic HeartFailure (CHF) is a syndrome that negatively affects a person's Quality of Life (QOL). The efficient self-management education program increases the individual's abilities and skills for following and participating in a long-term healthcare plan.The aim of this study was to determine the effect of the self-management education program on QOL (...) sessions followed for a 3-month period. The Iranian heartfailure QOL questionnaire was used for data collection before and after the intervention. The independent-samples and paired-samples t-tests, Chi-square and Fisher exact tests were used for data analysis via the SPSS v.16 software. P<0.05 was considered statistically significant.No statistically significant differences were reported between the groups in terms of demographic and clinical characteristics, indicating that they were homogeneous
Identifying cutâ€off scores for interpretation of the HeartFailure Impact Questionnaire Heartfailure (HF) influences health-related quality of life. However, the factors that contribute to health-related quality of life remain unclear in Taiwan. We aim to identify the factors influencing health-related quality of life in HF patients.Hospitalized HF (N = 225) patients were included from April 2011 to April 2014. Health-related quality of life was assessed by using the 36-Item Short-Form (...) Health Survey (SF-36) and the Minnesota Living with HeartFailure Questionnaire. A new cut-off was conducted based on the combination of SF-36 and Minnesota Living with HeartFailure questionnaire.There were significant differences between good and poor quality groups on age, gender, education levels, occupational classification caregiver, New York Heart Association classes, and the numbers of comorbidities. The logistic regression analysis showed that the number of comorbidities was more than three
for HeartFailure) trial, we are investigating whether these acute haemodynamic improvements translate into improvements in exercise capacity and heartfailure symptoms.This multicentre, double-blind, randomized, crossover study aims to randomize 160 patients with PR prolongation (≥200 ms), LV impairment (EF ≤ 40%), and either narrow QRS (≤140 ms) or right bundle branch block. All patients receive a cardiac device with leads positioned in the right atrium and the His bundle. Eligible patients also (...) Rationale and design of the randomized multicentre His Optimized Pacing Evaluated for HeartFailure (HOPEâ€HF) trial In patients with heartfailure and a pathologically prolonged PR interval, left ventricular (LV) filling can be improved by shortening atrioventricular delay using His-bundle pacing. His-bundle pacing delivers physiological ventricular activation and has been shown to improve acute haemodynamic function in this group of patients. In the HOPE-HF (His Optimized Pacing Evaluated
studied subjects with HFpEF (n = 28) and HFrEF (n = 25) and without HF (n = 71). Left ventricular (LV) mass and left atrial (LA) volumes were measured with cardiac magnetic resonance imaging. Arginine vasopressin and ANP were measured with enzyme-linked immunosorbent assay. Arginine vasopressin levels were significantly greater in HFpEF [0.96 pg/mL; 95% confidence interval (CI) = 0.83-1.1 pg/mL] compared with subjects without HF (0.69 pg/mL; 95% CI = 0.6-0.77 pg/mL; P = 0.0002). Heartfailure (...) Association of arginine vasopressin with low atrial natriuretic peptide levels, left ventricular remodelling, and outcomes in adults with and without heartfailure The arginine vasopressin (AVP) pathway has been extensively studied in heartfailure (HF) with reduced ejection fraction (HFrEF), but less is known about AVP in HF with preserved EF (HFpEF). Furthermore, the association between AVP and atrial natriuretic peptide (ANP, a well-known inhibitor of AVP secretion) in HF is unknown.We
Heartfailure Evidence Maps - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4
Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heartfailure with preserved ejection fraction. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system improve survival and reduce morbidity in people with heartfailure with reduced left ventricular ejection fraction. There is uncertainty whether these treatments are beneficial for people with heartfailure with preserved ejection fraction and a comprehensive review of the evidence (...) is required.To assess the effects of beta-blockers, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor neprilysin inhibitors, and mineralocorticoid receptor antagonists in people with heartfailure with preserved ejection fraction.We searched CENTRAL, MEDLINE, Embase and two clinical trial registries on 25 July 2017 to identify eligible studies. Reference lists from primary studies and review articles were checked for additional studies. There were no language